Laverock Therapeutics has announced key in-vivo functional milestones across its T-cell and macrophage oncology programmes for solid tumour indications....
Sparrow Pharmaceuticals, Inc. has announced positive phase 2 clinical data for clofutriben, its lead investigational 11β-hydroxysteroid dehydrogenase type 1...